Prescription Drug Information: KOSELUGO

KOSELUGO- selumetinib capsule
AstraZeneca Pharmaceuticals LP

1 INDICATIONS AND USAGE

KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

The recommended dosage of KOSELUGO is 25 mg/m2 orally twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity.

KOSELUGO can be taken with or without food [see Clinical Pharmacology (12.3)]. The recommended dose of KOSELUGO based on body surface area (BSA) is shown in Table 1.

Table 1 Recommended Dosage Based on Body Surface Area
*
The recommended dosage for patients with a BSA less than 0.55 m2 has not been established.

Body Surface Area *

Recommended Dosage

0.55 – 0.69 m2

20 mg in the morning and 10 mg in the evening

0.70 – 0.89 m2

20 mg twice daily

0.90 – 1.09 m2

25 mg twice daily

1.10 – 1.29 m2

30 mg twice daily

1.30 – 1.49 m2

35 mg twice daily

1.50 – 1.69 m2

40 mg twice daily

1.70 – 1.89 m2

45 mg twice daily

≥ 1.90 m2

50 mg twice daily

Swallow KOSELUGO capsules whole with water. Do not chew, dissolve or open capsule.

Do not administer to patients who are unable to swallow a whole capsule.

Do not take a missed dose of KOSELUGO unless it is more than 6 hours until the next scheduled dose.

If vomiting occurs after KOSELUGO administration, do not take an additional dose, but continue with the next scheduled dose.

2.2 Dosage Modifications for Adverse Reactions

The recommended dose reductions for adverse reactions are provided in Table 2.

Table 2 Recommended Dose Reductions for KOSELUGO for Adverse Reactions
*
Permanently discontinue KOSELUGO in patients unable to tolerate KOSELUGO after two dose reductions.

Body Surface Area

First Dose Reduction

(mg/dose)

Second Dose Reduction *

(mg/dose)

Morning

Evening

Morning

Evening

0.55 – 0.69 m2

10

10

10 mg once daily

0.70 – 0.89 m2

20

10

10

10

0.90 – 1.09 m2

25

10

10

10

1.10 – 1.29 m2

25

20

20

10

1.30 – 1.49 m2

25

25

25

10

1.50 – 1.69 m2

30

30

25

20

1.70 – 1.89 m2

35

30

25

20

≥ 1.90 m2

35

35

25

25

Dosage modifications for adverse reactions are in Table 3.

Table 3 Recommended Dosage Modifications for KOSELUGO for Adverse Reactions
Severity of Adverse Reaction Recommended Dosage Modifications for KOSELUGO

Cardiomyopathy [see Warnings and Precautions (5.1)]

Asymptomatic decrease in left ventricular ejection fraction (LVEF) of 10% or greater from baseline and less than lower level of normal

Withhold until resolution. Resume at reduced dose.

Symptomatic decreased LVEF
Grade 3 or 4 decreased LVEF

Permanently discontinue.

Ocular Toxicity [see Warnings and Precautions (5.2)]

Retinal Pigment Epithelial Detachment (RPED)

Withhold until resolution. Resume at reduced dose.

Retinal vein occlusion (RVO)

Permanently discontinue.

Gastrointestinal Toxicity [see Warnings and Precautions (5.3)]

Grade 3 Diarrhea

Withhold until improved to Grade 0 or 1. Resume at same dose. Permanently discontinue if no improvement within 3 days.

Grade 4 Diarrhea

Permanently discontinue.

Grade 3 or 4 Colitis

Permanently discontinue.

Skin Toxicity [see Warnings and Precautions (5.4)]

Grade 3 or 4

Withhold until improvement. Resume at reduced dose.

Increased Creatine Phosphokinase (CPK) [see Warnings and Precautions (5.5)]

Grade 4 Increased CPK
Any Increased CPK and myalgia

Withhold until improved to Grade 0 or 1. Resume at reduced dose. Permanently discontinue if no improvement within 3 weeks.

Rhabdomyolysis

Permanently discontinue.

Other Adverse Reactions [see Adverse Reactions (6.1)]

Intolerable Grade 2
Grade 3

Withhold KOSELUGO until improved to Grade 0 or 1. Resume at reduced dose.

Grade 4

Withhold KOSELUGO until improved to Grade 0 or 1. Resume at reduced dose. Consider discontinuation.

* Per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03

RxDrugLabels.com provides trustworthy package insert and label information about marketed prescription drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by RxDrugLabels.com. Every individual prescription drug label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

As a leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. RxDrugLabels.com provides the full prescription-only subset of the FDA's repository. Medication information provided here is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2024. All Rights Reserved.